Earnings ·
Evogene reports $7.7M net loss as revenues drop to $0.7M amid shareholder dispute
EVGNEvogene Ltd.
Evogene Ltd. reported unaudited financial results for the six months ended June 30, 2026, showing a net loss of $7.7 million compared to $7.7 million in the prior year period. Revenues decreased to approximately $0.7 million from $2.9 million, primarily due to lower seed sales by subsidiary Casterra. The company executed a warrant inducement transaction in February 2026, raising approximately $3.4 million through the exercise of existing warrants at a reduced price and issuing new warrants. Additionally, Evogene raised approximately $3.3 million via an ATM offering with A.G.P./Alliance Global Partner in July and August 2026. The filing notes that dissident shareholders have initiated proceedings under Israeli law following a contested annual meeting on September 4, 2026. Evogene operates in the biotechnology industry, utilizing AI-driven platforms to discover and optimize small molecules for pharmaceutical and agricultural applications.